Martin Felices, PhD

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation

Martin Felices

Contact Info

Mailing Address:
420 Delaware Street SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Barbara Porwit

Administrative Phone
612-624-5620

Administrative Email
porw0001@umn.edu

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation

Co-Director, Translation Therapy Shared Resource


PhD, University of Massachusetts Amherst, Amherst, MA

Summary

Dr. Felices received his Ph.D. in immunology from UMASS Medical School in 2008, where his research focused on innate and adaptive immune subsets. He then pursued an industry postdoctoral fellowship at Novartis Institutes for BioMedical Research, in Cambridge, MA, in the Developmental and Molecular Pathways group where he studied signaling pathways involved in liver injury and tumorigenesis. In 2011 he joined the University of Minnesota as a T32 postdoctoral fellow in the HOT division, focusing his research on Natural Killer (NK) cell biology, prior to becoming an assistant professor. Dr. Felices’ group focuses on methodologies to improve NK cell immunotherapy, with a particular focus on cytokine signaling and development NK specific biologics. In recent years Dr. Felices has been dedicating most of his effort on a Tri-specific Killer Engager (TriKE) platform to target NK cells to tumors while providing a cytokine signal.

Expertise

  • Biologic Design
  • Immunotherapy
  • Innate and Adaptive Immunology
  • Signal Transduction

Professional Associations

  • The American Association of Immunologists, Society for Natural Immunity

Research

Research Summary/Interests

  • NK cell biology (development, survival, and function)
  • Cancer immunology
  • Signal transduction
  • Immune metabolism
  • Immunotherapy Biologic
  • Cytokine signaling
  • Biologic design/production (bi- and tri-specifics)

Publications

  • Vallera, D. A., Ferrone, S., Kodal, B., Hinderlie, P., Bendzick, L., Ettestad, B., Hallstrom, C., Zorko, N. A., Rao, A., Fujioka, N., Ryan, C. J., Geller, M. A., Miller, J. S., & Felices, M. (2020). NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers, 12(9), 2659. doi: 10.3390/cancers12092659
  • Felices, M., Lenvik, T. R., Kodal, B., Lenvik, A. J., Hinderlie, P., Bendzick, L. E., Schirm, D. K., Kaminski, M. F., McElmurry, R. T., Geller, M. A., Eckfeldt, C. E., Vallera, D. A., & Miller, J. S. (2020). Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. Cancer Immunol Res, 8(9), 1139-1149. PMID: 32661096 doi: 10.1158/2326-6066.CIR-19-0837
  • Uppendahl, L. D.*, Felices, M.*, Bendzick, L., Ryan, C., Kodal, B., Hinderlie, P., Boylan KLM, Skubitz APN, Miller, J. S., & Geller, M. A. (2019). Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. Gynecol Oncol, 153(1), 149-157. PMID: 30658847 doi: 10.1016/j.ygyno.2019.01.006
    *Uppendahl LD and Felices M are co-first authors
  • Felices, M., Kodal, B., Hinderlie, P., Kaminski, M. F., Cooley, S., Weisdorf, D. J., Vallera, D. A., Miller, J. S., & Bachanova, V. (2019). Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Adv, 3(6), 897-907. PMID: 30890546 doi: 10.1182/bloodadvances.2018029371
  • Felices, M., Lenvik, A. J., McElmurry, R., Chu, S., Hinderlie, P., Bendzick, L., Geller, M. A., Tolar, J., Blazar, B. R., & Miller, J. S. (2018). Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight, 3(3). PMID: 29415897 doi: 10.1172/jci.insight.96219